Neurocrine Biosciences Inc (NBIX)

51.10
NASDAQ : Health Care
Prev Close 51.51
Day Low/High 50.67 / 52.12
52 Wk Low/High 37.34 / 55.15
Avg Volume 1.25M
Exchange NASDAQ
Shares Outstanding 87.11M
Market Cap 4.49B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

Wall Street Closes Lower Amid Continued Global Worries

Wall Street Closes Lower Amid Continued Global Worries

Stocks closed lower Wednesday as markets continue to grapple with geopolitical uncertainty.

2 Biotech Pullback Targets

2 Biotech Pullback Targets

Acadia and Neurocrine both have catalysts for growth; buy any weakness.

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks Fall as Wall Street Can't Shake Geopolitical Concerns

Stocks are lower on Wednesday as markets continue to grapple with geopolitical uncertainty.

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents

The company's shares were up 24% ahead of market's open on an FDA approval.

Neurocrine Announces FDA Approval Of INGREZZA™ (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD) (with Multimedia)

Neurocrine Announces FDA Approval Of INGREZZA™ (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD) (with Multimedia)

Provides significant and rapid reduction in involuntary movements with simple once-daily dosing

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug

The U.S. Food and Drug Administration granted Ingrezza a relatively clean label that does not include a black box safety warning against suicidality or depression.

Neurocrine Announces FDA Approval Of INGREZZA TM (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD)

Neurocrine Announces FDA Approval Of INGREZZA TM (valbenazine) Capsules As The First And Only Approved Treatment For Adults With Tardive Dyskinesia (TD)

Provides significant and rapid reduction in involuntary movements with simple once-daily dosing

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding In Women With Uterine Fibroids

- Elagolix, with or without add-back therapy, showed effective and rapid reduction of heavy menstrual bleeding compared to placebo in women with uterine fibroids

Neurocrine Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (valbenazine) For The Treatment Of Tardive Dyskinesia

Neurocrine Announces American Journal Of Psychiatry Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (valbenazine) For The Treatment Of Tardive Dyskinesia

- Phase III study conducted in patients with tardive dyskinesia shows significant and meaningful reduction in symptoms with INGREZZA

Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone

Neurocrine And BIAL Announce Exclusive North American Licensing Agreement For Opicapone

Expands Movement Disorder Franchise with Rights to Commercialize Late Stage Asset for Parkinson's Disease

Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2016 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2016 Results

Conference Call and Webcast Scheduled for Tuesday, February 14, 2017

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Analysts' Actions -- Ford, Intel, Whirlpool, Wynn and More

Here are Friday's top research calls, including upgrades for Ford, Intel and Wynn Resorts, and a downgrade for Whirlpool.

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients

The same Neurocrine drug, valbenazine, is currently under review at the FDA as a treatment for the movement disorder tardive dyskinesia.

Neurocrine Announces Completion Of Phase II Clinical Study Of VMAT2 Inhibitor INGREZZA™ (valbenazine) In Adults With Tourette Syndrome

Neurocrine Announces Completion Of Phase II Clinical Study Of VMAT2 Inhibitor INGREZZA™ (valbenazine) In Adults With Tourette Syndrome

Eight Week Study Assessed Safety, Tolerability and Efficacy in 124 Adult Subjects

Neurocrine Provides Update On FDA Advisory Committee For INGREZZA™ (valbenazine) For The Treatment Of Tardive Dyskinesia

Neurocrine Provides Update On FDA Advisory Committee For INGREZZA™ (valbenazine) For The Treatment Of Tardive Dyskinesia

Company to Host Conference Call and Webcast Today, January 5th at 4:30pm ET / 1:30pm PT

Neurocrine Biosciences To Present At The 35th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 35th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast will be on January 9, 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin To Step Down

Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin To Step Down

Will Continue to Support Company Over Extended Transition Period Through End of 2017

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences To Present At The 28th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast will be on November 30, 2016

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2016 London Healthcare Conference

Live Audio Webcast will be on November 16, 2016

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Neurocrine Biosciences To Present At The Credit Suisse 25th Annual Healthcare Conference

Live Audio Webcast will be on November 7, 2016